Imatinib, as an intensive treatment for B-ALL in IKZF1- deletion children, significantly reduces the risk of recurrence and improves the 5-year overall survival of patients (Yeoh et al., 2018). The gene discussed is IKZF1; the disease is acute lymphoblastic leukemia.